Flexion Therapeutics, Inc. (Nasdaq: FLXN) to Ring The Nasdaq Stock Market Opening Bell


ADVISORY, Oct. 22, 2014 (GLOBE NEWSWIRE) -- --

What: 

Flexion Therapeutics, Inc. (Nasdaq:FLXN), a specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies, will visit the Nasdaq MarketSite in Times Square. 

In honor of the occasion, Michael Clayman, Chief Executive Officer will ring the Opening Bell.

Where:

Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:

Thursday, October 23, 2014 – 9:15 a.m. to 9:30 a.m. ET 

Flexion Therapeutics, Inc. Media Contact: 
Lisa Davidson
(781) 305-7765
ldavidson@flexiontherapeutics.com

Nasdaq MarketSite: 
Christine Barna
(646) 441-5310 
Christine.Barna@nasdaq.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq.

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaq.

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/.

Webcast:

A webcast of the NASDAQ Opening Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.

Photos: 

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.

About Flexion Therapeutics, Inc. (Nasdaq:FLXN):

Flexion is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of novel pain therapies. The company is currently advancing a portfolio of injectable drug candidates that have the potential to provide better and more persistent analgesia compared with existing therapy. The company's lead program, FX006, is an intra-articular sustained release steroid in development for patients with moderate to severe OA pain. The company also has two additional product candidates, FX007, a locally administered TrkA receptor antagonist for post-operative pain, and FX005, an intra-articular, sustained-release p38 MAP kinase inhibitor for end-stage OA patients.

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets.  As the creator of the world’s first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,500 listed companies with a market value of over $8.8 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaq.com/ambition or www.nasdaqomx.com.

-NDAQA-


            

Tags